State Street Corp Biovie Inc. Transaction History

State Street Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.4 - $0.56 $58,382 - $81,735	-145,956 Reduced 83.32%	29,212 $11,000
Q1 2024 May 15, 2024	SELL	$0.53 - $1.89 $304 - $1,086	-575 Reduced 0.33%	175,168 $92,000
Q4 2023 Feb 14, 2024	BUY	$1.22 - $5.24 $105,377 - $452,605	86,375 Added 96.65%	175,743 $221,000
Q3 2023 Nov 14, 2023	BUY	$2.75 - $5.17 $19,250 - $36,190	7,000 Added 8.5%	89,368 $304,000
Q2 2023 Aug 14, 2023	BUY	$4.09 - $8.29 $217,408 - $440,663	53,156 Added 181.97%	82,368 $355,000
Q1 2023 May 15, 2023	BUY	$4.89 - $10.53 $44,010 - $94,770	9,000 Added 44.53%	29,212 $236,000
Q4 2022 Feb 14, 2023	BUY	$3.86 - $42.0 $19,686 - $214,200	5,100 Added 33.75%	20,212 $157,000
Q1 2022 May 16, 2022	BUY	$2.74 - $5.65 $854 - $1,762	312 Added 2.11%	15,112 $71,000
Q4 2021 Feb 14, 2022	BUY	$4.41 - $6.99 $65,268 - $103,452	14,800 New	14,800 $67,000

340K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $64.3M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.